Author

Lynn Farrugia

Observed name: LYNN FARRUGIA

Institution: Alnylam Pharmaceuticals (United States)

Observed institution: Alnylam Pharmaceuticals (United States)

OpenAlex ID: A5115827245

Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN‐APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer’s disease

2024 · Sharon Cohen, Simon Ducharme, et al. · Alzheimer s & Dementia · 12

Multiple‐Dose Results from an Ongoing Phase 1 Study of Mivelsiran, an Investigational RNA Interference Therapeutic Targeting Amyloid‐Beta Precursor Protein for Alzheimer’s Disease

2025 · Sharon Cohen, Simon Ducharme, et al. · Alzheimer s & Dementia · 4

Abstract WP108: Risk of Seizures Among Patients with Cerebral Amyloid Angiopathy – a Nationwide Retrospective Cohort Study in the United States

2026 · Neal Parikh, Jie Zhang, et al. · Stroke

Works count: 3

Citation count: 16

H-index: 2

I10-index: 1